PRISMA-combined a-blockers and antimuscarinics for ureteral stent-related symptoms: A meta-analysis

Medicine (United States)

Volumn 96, Issue 7, 2017, Pages

  Zhang, Yu Ming ^a   Chu, Pei ^a   Wang, Wen Jin ^a  

^a LANZHOU UNIVERSITY   (China)

Author keywords

Solifenacin; SRS; Tamsulosin; Terazosin; Tolterodine; Ureteric stent related discomfort

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT;

ARTICLE; COMBINATION DRUG THERAPY; DRUG EFFICACY; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; META ANALYSIS; MONOTHERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); STENT COMPLICATION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; URETER STENT; ADVERSE EFFECTS; HEMATURIA; PAIN; STENT; URETER; URINARY INCONTINENCE; URINARY TRACT INFECTIONS;

ADRENERGIC ALPHA-ANTAGONISTS; DRUG THERAPY, COMBINATION; HEMATURIA; HUMANS; MUSCARINIC ANTAGONISTS; PAIN; QUALITY OF LIFE; STENTS; URETER; URINARY INCONTINENCE; URINARY TRACT INFECTIONS;

EID: 85013671509     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000006098     Document Type: Article

References (30)

1. Auge BK, Preminger GM. Ureteral stents and their use in endourology. Curr Opin Urol 2002;12:217-22.
2. Althaus AB, Li K, Pattison E, et al. Rate of dislodgment of ureteral stents when using an extraction string after endoscopic urological surgery. J Urol 2015;193:2011-4.
3. Clayman RV. The use of stents in contemporary urology. J Urol 2004;172:2106.
4. Joshi HB, Stainthorpe A, Macdonagh RP, et al. Indwelling ureteral stents: evaluation of symptoms, quality of life and utility. J Urol 2003;169:1065-9.
5. Kuyumcuoglu U, Eryildirim B, Tuncer M, et al. Effectiveness of medical treatment in overcoming the ureteral double-J stent related symptoms. Can Urol Assoc J 2011;6:1-4.
6. Zhang P,Hu WL, Cheng B, et al. a1-blockers for the reduction of ureteric stent-related symptoms: a systematic review and meta-analysis. Exp Ther Med 2016;11:660-8. [J].
7. Zhou L, Cai X, Li H, et al. Effects of a-blockers, antimuscarinics, or combination therapy in relieving ureteral stent-related symptoms: a meta-analysis. J Endourol 2015;29:650-6.
8. Lee SJ, Yoo C, Oh CY, et al. Stent position is more important than a-blockers or anticholinergics for stent-related lower urinary tract symptoms after ureteroscopic ureterolithotomy: a prospective randomized study. Korean J Urol 2010;51:636-41.
9. Lim KT, Kim YT, Lee TY, et al. Effects of tamsulosin, solifenacin, and combination therapy for the treatment of ureteral stent related discomforts [J]. Korean J Urol 2011;52:485-8.
10. Tehranchi A, Rezaei Y, Khalkhali H, et al. Effects of terazosin and tolterodine on ureteral stent related symptoms: A double-blind placebocontrolled randomized clinical trial. Int Braz J Urol 2013;39:832-40.
11. Shalaby E, Ahmed AF, Maarouf A, et al. Randomized controlled trial to compare the safety and efficacy of tamsulosin, solifenacin, and combination of both in treatment of double-J stent-related lower urinary symptoms. Adv Urol 2013;2013:752382.
12. Shelbaia A, Elnashar A, Khairy H. MP20-10 Role of anticholinergics (tolterodine) and selective alpha-blocker (tamsulosin) in improving the lower urinary tract symptoms associated with double J ureteral stent placement after ureteroscopy. J Urol 2014;191:e199-200.
13. Streeper NM, Sivalingam S, Sehgal PD, et al. Does combination therapy with tamsulosin and tolterodine improve ureteral stent discomfort compared with tamsulosin alone? A double-blind, randomized controlled trial. J Urol 2014;191:S161-2.
14. Park J, Yoo C, Han DH, et al. A critical assessment of the effects of tamsulosin and solifenacin as monotherapies and as a combination therapy for the treatment of ureteral stent-related symptoms: a 2-2 factorial randomized trial. World J Urol 2015;33:1-8.
15. Sivalingam S, Streeper NM, Sehgal PD, et al. Does combination therapy with tamsulosin and tolterodine improve ureteral stent discomfort compared with tamsulosin alone? A double-blind, randomized, controlled trial. J Urol 2016;195:385-90.
16. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. Cochrane Collaboration [updated March 2011]. Available at: www.cochrane-handbook.org. Accessed 2016.
17. Sahebkar A, Serban C, Ursoniu S, et al. Effect of garlic on plasma lipoprotein (a) concentrations: a systematic review and meta-analysis of randomized controlled clinical trials. Nutrition 2016;32:33-40.
18. Dimitropoulos K, Gravas S. Solifenacin/tamsulosin fixed-dose combination therapy to treat lower urinary tract symptoms in patients with benign prostatic hyperplasia. Drug Design Devel Ther 2015;9:1707-16.
19. Wang H, Man LB, Huang GL, et al. Comparative efficacy of tamsulosin versus nifedipine for distal ureteral calculi: a meta-analysis. Drug Des Devel Ther 2016;10:1257-65.
20. Park SC, Jung SW, Lee JW, et al. The effects of tolterodine extended release and alfuzosin for the treatment of double-j stent-related symptoms. J Endourol 2009;23:1913-7.
21. el Din KE, Koch WF, de Wildt MJ, et al. Reliability of the international prostate symptom score in the assessment of patientswith lower urinary tract symptoms and/or benign, prostatic hyperplasia. J Urol 1996;155:1959-64.
22. Roosen A, Wu C, Chowdhury RA, et al. Characteristics of spontaneous activity in the bladder trigone. Eur Urol 2009;56:346-53.
23. Kwon JK, Kang SC, Oh CK, et al. The beneficial effect of alpha-blockers for ureteral stent-related discomfort: systematic review and network meta-analysis for alfuzosin versus tamsulosin versus placebo. BMC Urol 2015;15:1-0.
24. Park HK, Paick SH, Kim HG, et al. The impact of ureteral stent type on patient symptoms as determined by the ureteral stent symptom questionnaire: a prospective, randomized, controlled study. J Endourol 2014;29:367-71.
25. Irani J, Siquier J, Pirès C, et al. Symptom characteristics and the development of tolerance with time in patients with indwelling doublepigtail ureteric stents. BJU Int 1999;84:276-9.
26. Beddingfield R, Pedro RN, Hinck B, et al. Alfuzosin to relieve ureteral stent discomfort: a prospective, randomized, placebo controlled study. J Urol 2009;181:499-1499.
27. Jüni P, Egger M. Allocation concealment in clinical trials. JAMA 2002;288:2408-9.
28. Eveline N, Stephan R, Sven T, et al. The importance of allocation concealment and patient blinding in osteoarthritis trials: a metaepidemiologic study. Arthritis Rheumatol 2009;61:1633-41.
29. LangeD, Bidnur S,Hoag N, et al. Ureteral stent-associated complications-where we are and where we are going. Nat Rev Urol 2015;12:17-25.
30. Kicinski M, Springate DA, Kontopantelis E. Publication bias in metaanalyses from the Cochrane Database of Systematic Reviews. Stat Med 2015;34:2781-93.